CORE--ANALYSIS

核心--分析

• 批准号: 6501591
• 负责人: Neil R. Hackett
• 金额: $ 19.94万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6501591
• 关键词: bioimaging /biomedical imaging; biomedical facility; computer data analysis; cooperative study; gene therapy; immunology

The Analysis Core provides the Weill Cornell PEGT investigators access to advanced technologies in the general areas of biophysical analysis, quantitative assessment of DNA and RNA levels, biological imaging and host response to gene transfer vectors. To relieve PEGT investigators from the necessary to purchase expensive equipment and learn complex techniques, the group has been assembled under the direction by Neil Hackett Ph.D. and Philip Leopold Ph.D. Located primarily in the ninth floor of the Belfer Gene Therapy Core Facility, adjacent to the DNA Vector Core and Experimental Animal Core, the Analysis Core will interact with all Weill Cornell PEGT preclinical and clinical projects. In the area of new vector (RNA and DNA) development and characterization of clinical (GMP) vector preparations, the Analysis Core will perform biophysical methods including spectroscopy (NMR, UV/visible, fluorescent), transmission electron microscopy of negatively stained and frozen specimens, particle size and surface charge measurements and analytical HPLC. In support of PEGT projects the Analysis Core will enable pharmacokinetics and biodistribution studies by quantitative PCR, genotyping PCR, genotyping of hosts and analysis of gene expression profiles by array methods. The biological imaging facilities include photographic and quantitative digital data collection of visible and fluorescent micrographs, scanning and transmission EM, flow cytometry and a range of methods of sample preparation (immunohistochemistry, immunofluorescent, in situ hybridization). The host responses section will assist in assessment of humoral (antigen-0specific antibody by class, neutralizing antibody), cellular (T cell proliferation, cytotoxic T lymphocyte) and cytokine (ELISPOT, serum cytokine) responses to in vivo gene therapy with a particular focus on interpreting human response in the two clinical projects.

分析核心为威尔康奈尔 PEGT 研究人员提供了生物物理分析、DNA 和 RNA 水平定量评估、生物成像和宿主对基因转移载体反应等领域的先进技术。为了使 PEGT 调查人员无需购买昂贵的设备和学习复杂的技术，该小组是在 Neil Hackett 博士的指导下组建的。和菲利普·利奥波德博士分析核心主要位于贝尔弗基因治疗核心设施的九楼，毗邻 DNA 载体核心和实验动物核心，将与所有威尔康奈尔 PEGT 临床前和临床项目互动。在新载体（RNA和DNA）开发和临床（GMP）载体制剂表征领域，分析核心将执行生物物理方法，包括光谱（NMR、UV/可见光、荧光）、负染色和冷冻样本的透射电子显微镜、粒径和表面电荷测量以及分析型HPLC。为了支持 PEGT 项目，分析核心将通过定量 PCR、基因分型 PCR、宿主基因分型以及阵列方法分析基因表达谱来实现药代动力学和生物分布研究。生物成像设施包括可见光和荧光显微照片的照相和定量数字数据收集、扫描和透射电镜、流式细胞术以及一系列样品制备方法（免疫组织化学、免疫荧光、原位杂交）。宿主反应部分将协助评估体内基因治疗的体液（抗原0特异性抗体、中和抗体）、细胞（T细胞增殖、细胞毒性T淋巴细胞）和细胞因子（ELISPOT、血清细胞因子）反应，特别侧重于解释两个临床项目中的人类反应。